LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Considerations for managed care pharmacy in evaluating mavacamten, a novel agent for obstructive hypertrophic cardiomyopathy.

Photo from wikipedia

DISCLOSURES: Dr Taddei-Allen was a PRIME Education Moderator on Hypertrophic Cardiomyopathy CE at AMCP Nexus 2021; AJMC article on managed care considerations for hypertrophic cardiomyopathy. No funding was contributed toward… Click to show full abstract

DISCLOSURES: Dr Taddei-Allen was a PRIME Education Moderator on Hypertrophic Cardiomyopathy CE at AMCP Nexus 2021; AJMC article on managed care considerations for hypertrophic cardiomyopathy. No funding was contributed toward the writing of this commentary.

Keywords: managed care; hypertrophic cardiomyopathy; care pharmacy; considerations managed

Journal Title: Journal of managed care & specialty pharmacy
Year Published: 2022

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.